215 related articles for article (PubMed ID: 23280553)
21. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression.
Shukla S; Sharma H; Abbas A; MacLennan GT; Fu P; Danielpour D; Gupta S
PLoS One; 2013; 8(1):e53527. PubMed ID: 23308245
[TBL] [Abstract][Full Text] [Related]
23. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer.
Tolcher AW
Semin Oncol; 2001 Aug; 28(4 Suppl 15):67-70. PubMed ID: 11685732
[TBL] [Abstract][Full Text] [Related]
24. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
25. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.
Rayburn ER; Wang W; Zhang Z; Li M; Zhang R; Wang H
Prostate; 2006 Nov; 66(15):1653-63. PubMed ID: 16927305
[TBL] [Abstract][Full Text] [Related]
26. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
[TBL] [Abstract][Full Text] [Related]
27. Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc.
Hatano K; Yamaguchi S; Nimura K; Murakami K; Nagahara A; Fujita K; Uemura M; Nakai Y; Tsuchiya M; Nakayama M; Nonomura N; Kaneda Y
Mol Cancer Res; 2013 Sep; 11(9):1088-100. PubMed ID: 23788635
[TBL] [Abstract][Full Text] [Related]
28. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH
Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259
[TBL] [Abstract][Full Text] [Related]
29. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
Tzelepi V; Efstathiou E; Wen S; Troncoso P; Karlou M; Pettaway CA; Pisters LL; Hoang A; Logothetis CJ; Pagliaro LC
J Clin Oncol; 2011 Jun; 29(18):2574-81. PubMed ID: 21606419
[TBL] [Abstract][Full Text] [Related]
30. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
31. TNFAIP8 drives metabolic reprogramming to promote prostate cancer cell proliferation.
Niture S; Lin M; Odera JO; Moore J; Zhe H; Chen X; Suy S; Collins SP; Kumar D
Int J Biochem Cell Biol; 2021 Jan; 130():105885. PubMed ID: 33227392
[TBL] [Abstract][Full Text] [Related]
32. A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.
Xing ND; Ding ST; Saito R; Nishizawa K; Kobayashi T; Inoue T; Oishi S; Fujii N; Lv JJ; Ogawa O; Nishiyama H
Asian J Androl; 2011 Mar; 13(2):236-41. PubMed ID: 21297652
[TBL] [Abstract][Full Text] [Related]
33. Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness.
Wissing MD; De Morrée ES; Dezentjé VO; Buijs JT; De Krijger RR; Smit VT; Van Weerden WM; Gelderblom H; van der Pluijm G
Oncotarget; 2014 Sep; 5(17):7357-67. PubMed ID: 25277178
[TBL] [Abstract][Full Text] [Related]
34. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
[TBL] [Abstract][Full Text] [Related]
35. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy.
Sundaram S; Durairaj C; Kadam R; Kompella UB
Mol Cancer Ther; 2009 Jun; 8(6):1655-65. PubMed ID: 19509261
[TBL] [Abstract][Full Text] [Related]
36. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
Crea F; Duhagon Serrat MA; Hurt EM; Thomas SB; Danesi R; Farrar WL
Int J Cancer; 2011 Apr; 128(8):1946-54. PubMed ID: 20568112
[TBL] [Abstract][Full Text] [Related]
37. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor α-induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy.
Wang J; Gao H; Liu G; Gu L; Yang C; Zhang F; Liu T
Hum Pathol; 2018 Dec; 82():239-248. PubMed ID: 30107189
[TBL] [Abstract][Full Text] [Related]
39. Androgen-responsive tripartite motif 36 enhances tumor-suppressive effect by regulating apoptosis-related pathway in prostate cancer.
Kimura N; Yamada Y; Takayama KI; Fujimura T; Takahashi S; Kume H; Inoue S
Cancer Sci; 2018 Dec; 109(12):3840-3852. PubMed ID: 30238687
[TBL] [Abstract][Full Text] [Related]
40. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
